Deng Wei-Qing, Ye Zi-Han, Tang Zhenghai, Zhang Xiao-Lei, Lu Jin-Jian
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China.
Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Macao 999078, China.
Acta Pharm Sin B. 2025 Feb;15(2):757-791. doi: 10.1016/j.apsb.2024.11.018. Epub 2024 Nov 28.
CD47 is an immune checkpoint widely regarded as a 'don't eat me' signal. CD47-based anti-cancer therapy has received considerable attention, with a significant number of clinical trials conducted. While anti-cancer therapies based on CD47 remain a focal point of interest among researchers, it is noteworthy that an increasing number of studies have found that CD47-based therapy ameliorated the pathological status of non-cancer diseases. This review aims to provide an overview of the recent progress in comprehending the role of CD47-based therapy in non-cancer diseases, including diseases of the circulatory system, nervous system, digestive system, and so on. Furthermore, we sought to delineate the promising mechanisms of CD47-based therapy in treating non-cancer diseases. Our findings suggest that CD47-based agents may exert their effect by regulating phagocytosis, regulating T cells, dendritic cells, and neutrophils, and regulating the secretion of cytokines and chemokines. Additionally, we put forward the orientation of further research to bring to light the potential of CD47 and its binding partners as a target in non-cancer diseases.
CD47是一种被广泛视为“别吃我”信号的免疫检查点。基于CD47的抗癌疗法备受关注，已经开展了大量临床试验。虽然基于CD47的抗癌疗法仍是研究人员关注的焦点，但值得注意的是，越来越多的研究发现基于CD47的疗法改善了非癌症疾病的病理状态。本综述旨在概述在理解基于CD47的疗法在非癌症疾病（包括循环系统、神经系统、消化系统等疾病）中的作用方面的最新进展。此外，我们试图阐明基于CD47的疗法治疗非癌症疾病的潜在机制。我们的研究结果表明，基于CD47的药物可能通过调节吞噬作用、调节T细胞、树突状细胞和中性粒细胞以及调节细胞因子和趋化因子的分泌来发挥作用。此外，我们提出了进一步研究的方向，以揭示CD47及其结合伙伴作为非癌症疾病靶点的潜力。
